Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 1 min 41 sec ago

Biogen’s IMRALDI®, an Adalimumab Biosimilar Candidate Referencing Humira®, Granted Positive Opinion by Committee for Medicinal Products for Human Use

Fri, 23/06/2017 - 08:50
ZUG, Switzerland--(BUSINESS WIRE)--The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for IMRALDI® (also known as SB5), an adalimumab biosimilar candidate referencing Humira®.1 The positive opinion will now be referred to the European Commission (EC), which grants marketing authorization for medicines in the European Union (EU). IMRALDI marks the third anti-TNF candidate to be submitted to the EMA by Samsung Bioepis, th

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting

Fri, 23/06/2017 - 03:49
CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that data from two Phase 1/2 clinical trials evaluating NINLARO™ (ixazomib) in patients with newly diagnosed multiple myeloma will be presented during oral sessions at the 2017 European Hematology Association (EHA) annual meeting on Saturday, June 24, 11:45 a.m. – 12 p.m. CEST and Sunday, June 25, 8:15 a.m. – 8:30 a.m. CEST. Both studies evaluated NINLARO plus lenalidomide and dex

Acerus Announces Voting Results for the 2017 Annual General Meeting

Thu, 22/06/2017 - 17:48
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the voting results from its Annual General Meeting held on June 22, 2017 in Toronto, Ontario. The total number of shares represented in person or by proxy at the meeting was 121,191,442, representing 56.87% of the total issued and outstanding Acerus shares. Election of Directors The six (6) candidates nominated for election to the Acerus Board of Directors and listed in the Company's Management Information Ci

Aurinia Announces Results of Annual General Meeting

Thu, 22/06/2017 - 16:48
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Announces Results of Annual General Meeting

Repare Therapeutics Raises US$68 Million Series A

Thu, 22/06/2017 - 05:46
MONTREAL & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Repare Therapeutics Inc. today announced a US$68 million Series A financing to advance its platform and pipeline of novel medicines that target genetically defined weaknesses of cancers. Founding investor Versant Ventures co-led the round with MPM Capital. They were also joined by other syndicate investors including Fonds de solidarité FTQ, Celgene Switzerland, an affiliate of Celgene Corporation, and BDC Capital’s Healthcare Venture Fund. With this

Bionext Launches Biosight: an Online Platform That Will Revolutionize Pharmaceutical Research

Wed, 21/06/2017 - 09:43
STRASBOURG, France--(BUSINESS WIRE)--Bionext, a bioinformatics company, announces today the launch of BioSight, an online bio-simulation platform designed for efficient identification of possible side effects of potential drug treatments on the human body. As result of fifteen years of molecular biology R&D, BioSight uses a patented algorithm that is able to predict all of the potential biological targets that are at risk of interacting with a potential drug treatment. Available as Software

Antibe Therapeutics Inc. Announces Closing of Public Offering

Wed, 21/06/2017 - 09:43
TORONTO--(BUSINESS WIRE)--ANTIBE THERAPEUTICS INC. ANNOUNCES CLOSING OF PUBLIC OFFERING

Covalon Announces Issuance of Stock Options

Wed, 21/06/2017 - 07:42
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV:COV), an advanced medical technologies company, today announced the issuance of an aggregate of 422,500 stock options to employees and consultants of the Company. The stock options will vest over three years and will be exercisable for a period of five years at an exercise price of $2.47 per stock option. About Covalon Covalon Technologies Ltd. researches, develops and commercializes new healthca

Aurinia to Host Annual General Meeting of Shareholders and Webcast on June 21 in Vancouver, BC

Wed, 21/06/2017 - 07:42
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced that the Company will be hosting its Annual General Meeting of Shareholders at 9 a.m. (Pacific Time) in Vancouver, BC. An audio webcast can be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website. About Aurinia Aurinia is a c

BIOQuébec and MassBio Announce the Signing of a Memorandum of Cooperation Agreement

Tue, 20/06/2017 - 14:39
SAN DIEGO--(BUSINESS WIRE)--#BIO2017--BIOQuébec and MassBio announce the signing of a memorandum of cooperation agreement to facilitate business ties between their respective members.

Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer

Tue, 20/06/2017 - 07:38
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen (NASDAQ: BIIB) announced today the appointment of Ginger Gregory, PhD, as Executive Vice President, Chief Human Resources Officer, effective July 17. Gregory, who was most recently the Chief Human Resources Officer at Shire Pharmaceuticals, brings more than 20 years of human resources experience to Biogen. She will now lead the company’s global HR function and organizational strategy and will serve as a member of Biogen’s Executive Committee. “It is exc

New Study Compares Performance of Masimo Next Generation SedLine® Patient State Index (PSi) to Original PSi During Anesthesia

Mon, 19/06/2017 - 08:33
GENEVA--(BUSINESS WIRE)--Masimo announced an abstract presented at Euroanaesthesia 2017 in which researchers compared original and Next Generation versions of Masimo PSi.

Canadian Biotech Goes Global

Mon, 19/06/2017 - 07:33
SAN DIEGO & OTTAWA, Ontario--(BUSINESS WIRE)--BIOTECanada launched BIO 2017 by chairing the annual meeting of International Council of Biotechnology Associations (ICBA) which brings together the national industry associations of the twenty leading biotechnology nations around the world. “I welcome the opportunity to Chair the ICBA,” commented Andrew Casey, President and CEO BIOTECanada. “BIOTECanada looks forward to helping shape the industry’s international public policy agenda, showcasing ind

Covalon Announces Voting Results from 2017 Annual Meeting of Shareholders

Fri, 16/06/2017 - 17:20
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced the results of the matters voted upon at the Company’s 2017 Annual Meeting of shareholders held June 15, 2017. Shareholders voted in favour of all items of business and each was approved by the requisite number of votes. The matters included the election of the board of directors, the appointment of auditors, and the approval of the

Cerveau Technologies, Inc. Announces FDA Acceptance of Investigational New Drug (IND) for Tau Imaging Agent MK-6240

Fri, 16/06/2017 - 08:18
BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced that the United States Food and Drug Administration has cleared their IND for [18F]MK-6240, an investigational tau imaging agent. Cerveau plans to work with partners to study the use of this product in Positron Emission Tomography (PET) scans for assessing the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, includ

Voclosporin Remission Data from the Phase IIb AURA-LV Study Highlighted at EULAR 2017

Fri, 16/06/2017 - 08:18
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”) a clinical stage biopharmaceutical company focused on the global immunology market, presented new duration of remission data from its global Phase IIB AURA-LV (AURA) study in lupus nephritis (LN) during the Annual European Congress of Rheumatology (EULAR) 2017 in Madrid, Spain. The presentation was made during the late-breaking session by Prof. Vladimir A. Dobronravov,

Antibe Therapeutics Inc. Announces Filing of Final Short Form Prospectus

Thu, 15/06/2017 - 13:13
TORONTO--(BUSINESS WIRE)--ANTIBE THERAPEUTICS INC. ANNOUNCES FILING OF FINAL SHORT FORM PROSPECTUS

New International Survey Shows Overwhelming Support for Very Low Nicotine Cigarettes

Thu, 15/06/2017 - 10:12
CLARENCE, N.Y.--(BUSINESS WIRE)--New International Survey Shows Overwhelming Support for Very Low Nicotine Cigarettes

Merck Becomes Member of the Worldwide Innovative Network in Personalized Cancer Medicine - WIN Consortium (Paris)

Thu, 15/06/2017 - 06:11
PARIS & DARMSTADT, Germany--(BUSINESS WIRE)--Merck becomes member of the Worldwide Innovative Network in Personalized Cancer Medicine - WIN Consortium (Paris).

Acerus Announces Licensing of NATESTO® in Major European Countries

Wed, 14/06/2017 - 17:08
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the signing of an agreement granting medac Gesellschaft für klinische Spezialpräparate mbH (“medac”) the exclusive right to market NATESTO® in 15 European countries (Germany, United Kingdom, France, Italy, Czech Republic, Slovakia, Spain, Sweden, Finland, Denmark, Norway, Poland, Austria, Netherland and Belgium). medac is a German pharmaceutical company with business in 80 countries and more than 1,200 employ

Pages